Jenburkt PharmaceuticalsBOM:524731 -1.47%81 Dividend Yield % is 1.62% as of Jul. 01, 2026, which is 4% below its 10-year median of 1.69. GuruFocus rates BOM:524731 with a GF Score™ of 81/100 and a GF Value™ of ₹1,111.70 (Fairly Valued). The stock has 1 warning sign investors should review. Among 516 Drug Manufacturers companies, Jenburkt Pharmaceuticals ranks worse than 57.17% on this metric.
As of today (2026-07-01), the Trailing Annual Dividend Yield of Jenburkt Pharmaceuticals is 1.62%.
The historical rank and industry rank for Jenburkt Pharmaceuticals's Dividend Yield % or its related term are showing as below:
BOM:524731'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.17 Med: 1.69 Max: 6.14
Current: 1.62
During the past 13 years, the highest Dividend Yield of Jenburkt Pharmaceuticals was 6.14%. The lowest was 0.17%. And the median was 1.69%.
BOM:524731's Dividend Yield % is ranked worse than 57.17% of 516
companies
in the Drug Manufacturers industry
Industry Median: 1.965
vs BOM:524731: 1.62
During the past 12 months, Jenburkt Pharmaceuticals's average Dividends Per Share Growth Rate was 17.60% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 14.50% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Jenburkt Pharmaceuticals was 172.90% per year. The lowest was -40.20% per year. And the median was 16.90% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524731 vs ZTS, UTHR: Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jenburkt Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jenburkt Pharmaceuticals Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jenburkt Pharmaceuticals's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Jenburkt Pharmaceuticals's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Jenburkt Pharmaceuticals Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
INR 18.000000
2025-07-11
2025-07-11
2025-07-24
Cash Dividend
annually
INR:INR 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jenburkt Pharmaceuticals (BOM:524731) has a Dividend Yield % of 1.62% as of Jul. 01, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Jenburkt Pharmaceuticals and its competitors. This is near median its historical median of 1.69. Over the past decade, Jenburkt Pharmaceuticals' Dividend Yield % has ranged from 0.17 to 6.14. According to the industry distribution chart, Jenburkt Pharmaceuticals ranks #295 out of 516 companies in the Drug Manufacturers industry, placing it in the top 57.2%.
Is Jenburkt Pharmaceuticals' Dividend Yield % too high?
Jenburkt Pharmaceuticals' current Dividend Yield % of 1.62% is near median its 10-year median of 1.69. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 6.14. The Drug Manufacturers industry median Dividend Yield % is 1.97. Jenburkt Pharmaceuticals' value of 1.62% is 17.6% below this industry median. Based on the distribution chart, Jenburkt Pharmaceuticals ranks #295 out of 516 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Jenburkt Pharmaceuticals has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jenburkt Pharmaceuticals' Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jenburkt Pharmaceuticals ranks #295 out of 516 companies for Dividend Yield %. This places Jenburkt Pharmaceuticals in the lower half of its industry. The industry median Dividend Yield % is 1.97. Jenburkt Pharmaceuticals' value of 1.62% is 17.6% below this benchmark. Historically, Jenburkt Pharmaceuticals' own Dividend Yield % has ranged from 0.17 to 6.14 over the past decade. While the company's 10-year median is 1.69 vs. the industry median of 1.97, Jenburkt Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 1.97, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jenburkt Pharmaceuticals's current Dividend Yield % of 1.62% is 17.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Jenburkt Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jenburkt Pharmaceuticals's current Dividend Yield % is 1.62%, which is near median its own 10-year median of 1.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jenburkt Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jenburkt Pharmaceuticals (BOM:524731) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,111.70, compared to a current price of ₹1,109.65 — trading 0.2% below its estimated fair value. The current Dividend Yield % is 1.62%, which is near median its 10-year median of 1.69 and 17.6% below the Drug Manufacturers industry median of 1.97. Jenburkt Pharmaceuticals' overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Jenburkt Pharmaceuticals (BOM:524731), the current Dividend Yield % is 1.62% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jenburkt Pharmaceuticals (BOM:524731) Overvalued in 2026?
Based on GuruFocus' analysis, Jenburkt Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹1,109.65 is trading 0.2% below its estimated GF Value™ of ₹1,111.70.
GuruFocus considers Jenburkt Pharmaceuticals to be Fairly Valued.
Key valuation signals for BOM:524731:
Dividend Yield %: 1.62% (near median its 10-year median of 1.69)
GF Value™: ₹1,111.70 vs. price of ₹1,109.65 (0.2% below fair value)
Industry Position: 17.6% below the Drug Manufacturers median (#295 of 516)
No single metric tells the full story. See the BOM:524731 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jenburkt Pharmaceuticals Ltd is engaged in the manufacturing, producing, developing, and marketing of pharmaceutical formulations. The company operates in one segment - pharmaceutical formulations. The company generates key revenue from the local market.
81GF Score
Get the complete analysis for BOM:524731
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524731 has been successfully added to your 
